Else Nutrition - CEO, Hamutal Yitzhak.
CEO, Hamutal Yitzhak.
Source: YouTube.
  • Else Nutrition (BABY) has successfully completed the first commercial trial run of its plant-based infant formula for age 0 -12 months
  • The successful trial run brings Else closer to commercializing a minimally processed, plant-based option
  • Else Nutrition GH Ltd. is an Israel-based food and nutrition company
  • Else Nutrition Holdings Inc. (BABY) opened trading at C$2.47 per share

Else Nutrition (BABY) has successfully completed the first commercial trial run of its plant-based infant formula for age 0 -12 months.

The trial run leveraged a first-of-its-kind technological development with one of the raw ingredients in the plant-based formulation, resulting in a cleaner ingredient, while keeping the nutritional value fully intact.

Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition commented on the success of the trial run.

“This successful trial is a major step for the company, as we move forward to provide real choice when it comes to dairy-free infant formula. The $90 billion global infant formula market has been dominated by dairy and soy for too long. This development brings us one step closer to commercializing a minimally processed, plant-based option to millions of wanting families globally.” 

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults.

Else Nutrition Holdings Inc. (BABY) opened trading at C$2.47 per share.

More From The Market Online

Air Canada adds new in-flight sports channels before NHL playoffs

Air Canada (TSX:AC) adds three new live TV sports channels for its in-flight entertainment system just in time for the Stanley Cup Playoffs

Thomson Reuters expands its GenAI assistant

Thomson Reuters (TSX:TRI) has revealed the expanded vision for its professional-grade GenAI assistant, CoCounsel.